

Yoon Jun Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1984274/publications.pdf>

Version: 2024-02-01

296
papers

9,337
citations

50244

46
h-index

66879

78
g-index

298
all docs

298
docs citations

298
times ranked

12210
citing authors

#	ARTICLE	IF	CITATIONS
1	Supraclavicular versus infraclavicular approach for ultrasound-guided right subclavian venous catheterisation: a randomised controlled non-inferiority trial. <i>Anaesthesia</i> , 2022, 77, 59-65.	1.8	14
2	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	2.4	9
3	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	1.8	48
4	Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 387-394.	1.4	10
5	Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. <i>Liver International</i> , 2022, 42, 320-329.	1.9	7
6	Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. <i>Hepatology</i> , 2022, 76, 492-501.	3.6	26
7	Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 433-433.	0.8	6
8	Nonalcoholic Fatty Liver Disease Is a Precursor of New-Onset Metabolic Syndrome in Metabolically Healthy Young Adults. <i>Journal of Clinical Medicine</i> , 2022, 11, 935.	1.0	6
9	Platelet-to-White Blood Cell Ratio Is Associated with Adverse Outcomes in Cirrhotic Patients with Acute Deterioration. <i>Journal of Clinical Medicine</i> , 2022, 11, 2463.	1.0	5
10	Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>Diagnostics</i> , 2022, 12, 1170.	1.3	7
11	Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail. <i>Cancers</i> , 2022, 14, 2617.	1.7	4
12	Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 425-472.	4.5	14
13	Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 976-986.e5.	2.4	13
14	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021, 27, 713-718.	3.2	27
15	Association of Metabolic Risk Factors With Risks of Cancer and All-Cause Mortality in Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2021, 73, 2266-2277.	3.6	45
16	Lung Shunt Reduction for Yttrium-90 Radioembolization: Chemoembolization versus Radioembolization. <i>In Vivo</i> , 2021, 35, 2305-2312.	0.6	3
17	Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode. <i>Korean Journal of Radiology</i> , 2021, 22, 179.	1.5	8
18	Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 346-359.	4.5	10

#	ARTICLE	IF	CITATIONS
19	Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Virtual Tumor Absorbed Dose as a Predictor of Complete Response. <i>Anticancer Research</i> , 2021, 41, 2625-2635.	0.5	2
20	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 587-598.	1.8	1
21	Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. <i>Cut and Liver</i> , 2021, 15, 895-903.	1.4	3
22	Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 613-623.	1.8	9
23	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1392-1399.	1.0	13
24	Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor. <i>Cancer Gene Therapy</i> , 2021, , .	2.2	4
25	IDDF2021-ABS-0080â€¦96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity. , 2021, , .		0
26	Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B. <i>Hepatology</i> , 2021, 74, 1737-1749.	3.6	27
27	Prospective Multi-Center Korean Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolics for Nodular Hepatocellular Carcinoma: A Two-Year Outcome Analysis. <i>Korean Journal of Radiology</i> , 2021, 22, 1658.	1.5	10
28	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00290.	1.3	9
29	Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial. <i>Liver Cancer</i> , 2021, 10, 72-81.	4.2	19
30	No-Touch vs. Conventional Radiofrequency Ablation Using Twin Internally Cooled Wet Electrodes for Small Hepatocellular Carcinomas: A Randomized Prospective Comparative Study. <i>Korean Journal of Radiology</i> , 2021, 22, 1974.	1.5	18
31	Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 6009.	1.7	9
32	Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1565-1577.	1.8	12
33	The Change in Metabolic Syndrome Status and the Risk of Nonviral Liver Cirrhosis. <i>Biomedicines</i> , 2021, 9, 1948.	1.4	4
34	The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 370-377.	1.1	0
35	Prognosis of surgical hernia repair in cirrhotic patients with refractory ascites. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2020, 24, 481-488.	0.9	3
36	Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: A Multicenter Study. <i>Cancers</i> , 2020, 12, 2791.	1.7	25

#	ARTICLE	IF	CITATIONS
37	P914 Changes of echocardiographic parameters in primary mitral regurgitation and determinants of symptom: an assessment from the Asian valve registry data. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, .	0.5	0
38	P1274 Early surgery versus watchful waiting in patients with moderate aortic stenosis and left ventricular systolic dysfunction. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, .	0.5	0
39	Radioembolization-induced Tumor Calcifications as a Surrogate Marker of Tumor Response in Patients With Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2020, 40, 4191-4198.	0.5	7
40	Risk of Liver Cirrhosis and Hepatocellular Carcinoma after Fontan Operation: A Need for Surveillance. <i>Cancers</i> , 2020, 12, 1805.	1.7	23
41	Glecaprevir and pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 839-849.	3.7	32
42	Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1217-1225.	0.2	16
43	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	1.1	3
44	Combination of 1 st and 2 nd Week Dosing of Glass Yttrium-90 Microspheres for Superselective Radioembolization. <i>In Vivo</i> , 2020, 34, 2763-2768.	0.6	4
45	A non-synonymous variant rs12614 of complement factor B associated with risk of chronic hepatitis B in a Korean population. <i>BMC Medical Genetics</i> , 2020, 21, 241.	2.1	0
46	CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. <i>BMC Cancer</i> , 2020, 20, 1001.	1.1	4
47	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	6.1	20
48	Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1960-1968.	1.4	13
49	P1368 Effect of angiotensin receptor blocker in patients with moderate or severe aortic stenosis: a randomized controlled trial. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, .	0.5	0
50	Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1341-1349.	2.0	1
51	Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study. <i>Journal of Clinical Oncology</i> , 2020, 38, e16680-e16680.	0.8	5
52	Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study. <i>PLoS ONE</i> , 2020, 15, e0239733.	1.1	8
53	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 328-339.	4.5	32
54	Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2020, 14, 225-231.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485.	1.4	1
56	Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy. <i>Gut and Liver</i> , 2020, 14, 755-764.	1.4	17
57	Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B. <i>Gut and Liver</i> , 2020, 14, 377-386.	1.4	1
58	Impact of Interferon-Based Treatment on Quality of Life and Work-Related Productivity of Korean Patients with Chronic Hepatitis C. <i>Gut and Liver</i> , 2020, 14, 368-376.	1.4	3
59	Compositional differences in atherosclerosis between the major epicardial arteries; a secondary analysis from the PARADIGM study. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
60	Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986607.	1.4	21
61	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. <i>Cancers</i> , 2019, 11, 1721.	1.7	8
62	Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. <i>Cancers</i> , 2019, 11, 1295.	1.7	11
63	Additional fibrate treatment in UDCAâ€‘refractory PBC patients. <i>Liver International</i> , 2019, 39, 1776-1785.	1.9	24
64	Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. <i>Journal of Hepatology</i> , 2019, 71, 35-44.	1.8	29
65	Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1292.	1.8	32
66	Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 1093-1102.	1.8	107
67	Contact System Activation and Neutrophil Extracellular Trap Markers: Risk Factors for Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961882531.	0.7	36
68	A Model to Predict 1â€‘Month Risk of Transplant or Death in Hepatitis Aâ€‘Related Acute Liver Failure. <i>Hepatology</i> , 2019, 70, 621-629.	3.6	23
69	Non-hypervascular hepatobiliary phase hypointense nodules on gadoteric acid-enhanced MR can help determine the treatment method for HCC. <i>European Radiology</i> , 2019, 29, 3122-3131.	2.3	17
70	Hepatitis B virus X protein induces size-selective membrane permeabilization through interaction with cardiolipin. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2019, 1861, 729-737.	1.4	9
71	Cetylpyridinium chloride interaction with the hepatitis B virus core protein inhibits capsid assembly. <i>Virus Research</i> , 2019, 263, 102-111.	1.1	17
72	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 567-572.	1.2	44

#	ARTICLE	IF	CITATIONS
73	Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. <i>Journal of Hepatology</i> , 2019, 70, 684-691.	1.8	136
74	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 23-32.	2.0	62
75	Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1-8.	0.2	26
76	Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study. <i>Genes and Immunity</i> , 2019, 20, 1-9.	2.2	13
77	Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. <i>Journal of Liver Cancer</i> , 2019, 19, 128-135.	0.3	1
78	Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1062-1071.	1.1	23
79	Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. <i>European Radiology</i> , 2018, 28, 3513-3521.	2.3	24
80	Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 65-75.	4.2	23
81	Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B endemic area. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1490-1501.	1.9	22
82	Multiplatform Genomic Roadmap of Hepatocellular Carcinoma: A Matter of Molecular Heterogeneity. <i>Hepatology</i> , 2018, 68, 2029-2032.	3.6	14
83	A Model for Adaptive Decision Making of "Ablate-and-Wait" Versus Transplantation in Patients With Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 655-661.	1.1	1
84	Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2018, 50, 389-395.	0.4	18
85	Genetic association of complement component 2 variants with chronic hepatitis B in a Korean population. <i>Liver International</i> , 2018, 38, 1576-1582.	1.9	11
86	Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 707-717.	1.0	23
87	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. <i>BMC Cancer</i> , 2018, 18, 307.	1.1	18
88	Yttrium-90 Radioembolization of the Right Inferior Phrenic Artery in 20 Patients with Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 556-563.	0.2	19
89	Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. <i>Atherosclerosis</i> , 2018, 272, 137-144.	0.4	38
90	Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 68, 431-440.	1.8	147

#	ARTICLE	IF	CITATIONS
91	A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilization. <i>Journal of Viral Hepatitis</i> , 2018, 25, 412-420.	1.0	14
92	Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBsAg-positive high viral load chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2018, 25, 552-560.	1.0	11
93	Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, e18-e26.	1.1	13
94	Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio. <i>Gut and Liver</i> , 2018, 12, 714-721.	1.4	16
95	P2485 Longitudinal quantitative assessment of coronary plaque progression related to glycemic status using serial coronary computed tomography angiography. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
96	Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-9.	0.7	1
97	P2486 Differential association between the progression of coronary artery calcium and coronary plaque volume progression according to statins. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
98	Analysis of significant protein abundance from multiple reaction-monitoring data. <i>BMC Systems Biology</i> , 2018, 12, 123.	3.0	0
99	Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence. <i>Journal of Korean Medical Science</i> , 2018, 33, e283.	1.1	21
100	PI3K γ Is a Therapeutic Target in Hepatocellular Carcinoma. <i>Hepatology</i> , 2018, 68, 2285-2300.	3.6	35
101	Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. <i>Scientific Reports</i> , 2018, 8, 13651.	1.6	7
102	Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. <i>International Journal of Molecular Medicine</i> , 2018, 42, 2551-2559.	1.8	12
103	Transforming growth factor β 2 decreases side population cells in hepatocellular carcinoma in vitro. <i>Oncology Letters</i> , 2018, 15, 8723-8728.	0.8	7
104	A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. <i>Annals of Surgical Treatment and Research</i> , 2018, 94, 74.	0.4	56
105	Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1161-1171.	1.0	18
106	Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study. <i>Journal of Medical Virology</i> , 2018, 90, 1593-1603.	2.5	6
107	Comparison of switching bipolar ablation with multiple cooled wet electrodes and switching monopolar ablation with separable clustered electrode in treatment of small hepatocellular carcinoma: A randomized controlled trial. <i>PLoS ONE</i> , 2018, 13, e0192173.	1.1	14
108	Timing of upper gastrointestinal endoscopy does not influence short-term outcomes in patients with acute variceal bleeding. <i>World Journal of Gastroenterology</i> , 2018, 24, 5025-5033.	1.4	14

#	ARTICLE	IF	CITATIONS
109	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. <i>Cancer Research and Treatment</i> , 2018, 50, 366-373.	1.3	15
110	Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification. <i>Gut and Liver</i> , 2018, 12, 571-582.	1.4	6
111	Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding. <i>Gut and Liver</i> , 2018, 12, 704-713.	1.4	34
112	Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study. <i>Journal of Proteome Research</i> , 2017, 16, 1239-1248.	1.8	27
113	Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model. <i>Cancer Biology and Therapy</i> , 2017, 18, 67-75.	1.5	13
114	Perceived needs for the information communication technology (ICT)-based personalized health management program, and its association with information provision, health-related quality of life (HRQOL), and decisional conflict in cancer patients. <i>Psycho-Oncology</i> , 2017, 26, 1810-1817.	1.0	9
115	Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1073-1083.	1.9	56
116	Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. <i>Hepatology</i> , 2017, 66, 855-868.	3.6	35
117	Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. <i>Hepatology</i> , 2017, 66, 1556-1569.	3.6	92
118	Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 210-210.	1.9	0
119	Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. <i>Oncolmmunology</i> , 2017, 6, e1328335.	2.1	38
120	Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1312-1323.	2.5	25
121	Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. <i>Hepatology</i> , 2017, 66, 772-783.	3.6	37
122	Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 502-512.	0.2	34
123	Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 1407-1414.	1.9	33
124	Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. <i>Nature Communications</i> , 2017, 8, 839.	5.8	107
125	Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 845-855.	1.9	73
126	A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?. <i>Digestive and Liver Disease</i> , 2017, 49, 1273-1279.	0.4	5

#	ARTICLE	IF	CITATIONS
127	Prophylactic Temporary Occlusion of the Cystic Artery Using a Fibered Detachable Coil During 90Y Radioembolization. CardioVascular and Interventional Radiology, 2017, 40, 1624-1630.	0.9	13
128	Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. European Radiology, 2017, 27, 1448-1458.	2.3	31
129	Identification of novel <i>rs11209138</i> genetic variant associated with the risk of chronic hepatitis B in a Korean population. Liver International, 2017, 37, 354-361.	1.9	13
130	Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 347-354.	1.8	103
131	Thermal Injury-Induced Hepatic Parenchymal Hypoperfusion: Risk of Hepatocellular Carcinoma Recurrence after Radiofrequency Ablation. Radiology, 2017, 282, 880-891.	3.6	16
132	Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. PLoS ONE, 2017, 12, e0166188.	1.1	8
133	Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area. PLoS ONE, 2017, 12, e0170394.	1.1	11
134	3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells. PLoS ONE, 2017, 12, e0174271.	1.1	18
135	Current status and strategies for viral hepatitis control in Korea. Clinical and Molecular Hepatology, 2017, 23, 189-195.	4.5	21
136	Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients. Clinical and Molecular Hepatology, 2017, 23, 66-73.	4.5	13
137	Percutaneous Dual-Switching Monopolar Radiofrequency Ablation Using a Separable Clustered Electrode: A Preliminary Study. Korean Journal of Radiology, 2017, 18, 799.	1.5	12
138	Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis. Korean Journal of Internal Medicine, 2017, 32, 261-268.	0.7	8
139	Current status and strategies for hepatitis B control in Korea. Clinical and Molecular Hepatology, 2017, 23, 205-211.	4.5	89
140	Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget, 2017, 8, 47555-47564.	0.8	1
141	Acute Respiratory Failure Caused by Hepatopulmonary Fistula in a Patient with Hepatocellular Carcinoma. Tuberculosis and Respiratory Diseases, 2016, 79, 179.	0.7	4
142	Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14. PLoS ONE, 2016, 11, e0160822.	1.1	38
143	High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma. Journal of Medical Virology, 2016, 88, 1010-1017.	2.5	50
144	MicroRNA Profile of Granulosa Cells after Ovarian Stimulation Differs According to Maturity of Retrieved Oocytes. Geburtshilfe Und Frauenheilkunde, 2016, 76, 704-708.	0.8	11

#	ARTICLE	IF	CITATIONS
145	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. <i>Hepatology International</i> , 2016, 10, 947-955.	1.9	17
146	A phase 3b study of sofosbuvir plus ribavirin in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2016, 23, 358-365.	1.0	28
147	Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. <i>Biomedicine and Pharmacotherapy</i> , 2016, 83, 607-616.	2.5	30
148	Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. <i>Hepatology International</i> , 2016, 10, 909-915.	1.9	41
149	Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions. <i>Journal of Bioenergetics and Biomembranes</i> , 2016, 48, 581-590.	1.0	4
150	Prognostic stratification and nomogram for survival prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis. <i>British Journal of Radiology</i> , 2016, 89, 20160383.	1.0	10
151	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. <i>British Journal of Cancer</i> , 2016, 115, 1201-1205.	2.9	19
152	Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm. <i>Medicine (United States)</i> , 2016, 95, e4551.	0.4	13
153	Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. <i>Annals of Surgery</i> , 2016, 263, 842-850.	2.1	105
154	Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2568-2577.	1.1	22
155	17 β -estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 1247-1254.	1.0	24
156	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 852-860.	6.1	70
157	Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 1256-1264.	3.2	94
158	Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 132-138.e4.	2.4	117
159	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 1042-1051.	6.1	76
160	Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. <i>PLoS ONE</i> , 2016, 11, e0154986.	1.1	48
161	Switching Monopolar Radiofrequency Ablation Using a Separable Cluster Electrode in Patients with Hepatocellular Carcinoma: A Prospective Study. <i>PLoS ONE</i> , 2016, 11, e0161980.	1.1	14
162	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. <i>PLoS ONE</i> , 2016, 11, e0165722.	1.1	33

#	ARTICLE	IF	CITATIONS
163	Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 286-291.	4.5	15
164	Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e2159.	0.4	85
165	Sorafenib inhibits cancer side population cells by targeting c-Jun N-terminal kinase signaling. <i>Molecular Medicine Reports</i> , 2015, 12, 8247-8252.	1.1	7
166	JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs. <i>Molecular Medicine Reports</i> , 2015, 11, 263-268.	1.1	4
167	Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. <i>Journal of Medical Virology</i> , 2015, 87, 999-1007.	2.5	0
168	Association of <i>VAR2SFTS</i> polymorphisms with the risk of chronic hepatitis B in a Korean population. <i>Liver International</i> , 2015, 35, 1934-1940.	1.9	21
169	Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection. <i>Liver International</i> , 2015, 35, 1992-2000.	1.9	15
170	Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation. <i>Liver International</i> , 2015, 35, 2530-2536.	1.9	24
171	The association between microRNA-323b polymorphism and hepatitis B virus persistent infection – some problems should be addressed. <i>Journal of Viral Hepatitis</i> , 2015, 22, 626-626.	1.0	0
172	The Korean guideline for hepatocellular carcinoma surveillance. <i>Journal of the Korean Medical Association</i> , 2015, 58, 385.	0.1	14
173	Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0133935.	1.1	36
174	Hepatitis B Virus-Related Glomerulonephritis: Not a Predominant Cause of Proteinuria in Korean Patients with Chronic Hepatitis B. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-6.	0.7	4
175	Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. <i>World Journal of Gastroenterology</i> , 2015, 21, 6287.	1.4	51
176	Visceral Adipose Tissue Area as an Independent Risk Factor for Elevated Liver Enzyme in Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e573.	0.4	25
177	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 1383-1391.e6.	0.6	371
178	Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2037-2045.	1.2	16
179	Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in <i>Gulo</i> mice. <i>European Journal of Pharmacology</i> , 2015, 762, 247-255.	1.7	16
180	Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci of STAT4 and HLA-DQ in a Korean population. <i>Infection, Genetics and Evolution</i> , 2015, 33, 72-76.	1.0	36

#	ARTICLE	IF	CITATIONS
181	A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1666-1676.	2.9	73
182	Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 544-553.	5.7	36
183	Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 696-705.	1.4	13
184	The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection. <i>Journal of Medical Virology</i> , 2015, 87, 575-582.	2.5	14
185	Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 937-945.	0.9	7
186	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2015, 63, 320-328.	1.8	170
187	Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. <i>World Journal of Hepatology</i> , 2015, 7, 1553.	0.8	37
188	Drs. Lee et al respond:. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1250-1251.	0.2	0
189	Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. <i>Journal of Hepatology</i> , 2015, 63, 1086-1092.	1.8	49
190	Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 651-659.	0.2	32
191	Reduction of Oxidative Stress Attenuates Lipoapoptosis Exacerbated by Hypoxia in Human Hepatocytes. <i>International Journal of Molecular Sciences</i> , 2015, 16, 3323-3334.	1.8	6
192	Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: Risk of HCC recurrence after radiofrequency ablation. <i>Journal of Hepatology</i> , 2015, 62, 1122-1130.	1.8	70
193	Prominent protein Z-induced thrombin inhibition in cirrhosis: A new functional assay for hypercoagulability assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 784-793.	1.4	1
194	Association between information provision and decisional conflict in cancer patients. <i>Annals of Oncology</i> , 2015, 26, 1974-1980.	0.6	21
195	CLIF-SOFA scoring system accurately predicts short-term mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis. <i>Liver International</i> , 2015, 35, 46-57.	1.9	55
196	Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 972-978.	1.4	20
197	Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. <i>Liver International</i> , 2015, 35, 944-952.	1.9	49
198	Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2015, 10, e0130392.	1.1	8

#	ARTICLE	IF	CITATIONS
199	Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 150.	4.5	18
200	Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 358.	4.5	12
201	Post-treatment intracranial hemorrhage of brain metastases from hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2015, 33, 36.	0.7	4
202	Spontaneous Evolution in Bilirubin Levels Predicts Liver-Related Mortality in Patients with Alcoholic Hepatitis. <i>PLoS ONE</i> , 2014, 9, e100870.	1.1	18
203	Does 18F-FDG Positron Emission Tomography-Computed Tomography Have a Role in Initial Staging of Hepatocellular Carcinoma?. <i>PLoS ONE</i> , 2014, 9, e105679.	1.1	43
204	Association of Polymorphism in MicroRNA 604 with Susceptibility to Persistent Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma. <i>Journal of Korean Medical Science</i> , 2014, 29, 1523.	1.1	17
205	Does antiviral therapy reduce complications of cirrhosis?. <i>World Journal of Gastroenterology</i> , 2014, 20, 7306.	1.4	16
206	Prognostic stratification of brain metastases from hepatocellular carcinoma. <i>Journal of Neuro-Oncology</i> , 2014, 120, 209-214.	1.4	12
207	Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. <i>Journal of Viral Hepatitis</i> , 2014, 21, 873-881.	1.0	24
208	Small Single-Nodule Hepatocellular Carcinoma: Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting. <i>Radiology</i> , 2014, 271, 909-918.	3.6	97
209	Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. <i>Endocrine-Related Cancer</i> , 2014, 21, 343-353.	1.6	20
210	MicroRNA-196a polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2014, 86, 446-453.	2.5	19
211	High-sensitivity C-reactive Protein Level is an Independent Predictor of Poor Prognosis in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 444-449.	1.1	20
212	Prior Exposure to Lamivudine Increases Entecavir Resistance Risk in Chronic Hepatitis B Patients without Detectable Lamivudine Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1730-1737.	1.4	28
213	Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 133-144.	1.2	12
214	Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 259-264.	1.3	78
215	Association of a microRNA-323b polymorphism with the persistence of hepatitis B virus infection by the enhancement of viral replication. <i>Journal of Viral Hepatitis</i> , 2014, 21, 853-859.	1.0	17
216	Interleukin-8 is related to poor chemotherapeutic response and tumorigenicity in hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 341-350.	1.3	36

#	ARTICLE	IF	CITATIONS
217	Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 775-781.	1.4	59
218	Side population in <sc>LX2</sc> cells decreased by transforming growth factor α ² . <i>Hepatology Research</i> , 2014, 44, 229-237.	1.8	4
219	Efficacy of Entecavir-Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multidrug-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6710-6716.	1.4	32
220	Tauroursodeoxycholic Acid Attenuates Progression of Steatohepatitis in Mice Fed a Methionine α Choline-Deficient Diet. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1461-1474.	1.1	37
221	Relationship between polymorphisms near the <i><sc>IL</sc>28B</i> gene and spontaneous <sc>HB</sc>sAg seroclearance: a systematic review and meta α analysis. <i>Journal of Viral Hepatitis</i> , 2014, 21, 163-170.	1.0	16
222	Radiofrequency Ablation of Hepatocellular Carcinoma as First-Line Treatment: Long-term Results and Prognostic Factors in 162 Patients with Cirrhosis. <i>Radiology</i> , 2014, 270, 900-909.	3.6	256
223	Occult hepatitis B virus infection. <i>World Journal of Hepatology</i> , 2014, 6, 860.	0.8	81
224	Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization. <i>PLoS ONE</i> , 2014, 9, e90862.	1.1	11
225	Comparison of the Effects of Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma between Patients with and without Extrahepatic Metastases. <i>PLoS ONE</i> , 2014, 9, e113926.	1.1	17
226	Clinical outcomes of transjugular intrahepatic portosystemic shunt for portal hypertension: Korean multicenter real-practice data. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 18.	4.5	22
227	Hepatitis B viral load affects prognosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 12039.	1.4	50
228	A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 580.	0.7	16
229	Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 635-643.	1.2	32
230	Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. <i>Journal of Gastroenterology</i> , 2013, 48, 1401-1410.	2.3	35
231	Excellent Outcome in 238 Consecutive Living Donor Liver Transplantations Using the Right Liver Graft in a Large Volume Single Center. <i>World Journal of Surgery</i> , 2013, 37, 1419-1429.	0.8	21
232	Transarterial Chemoembolization with Additional Cisplatin Infusion for Hepatocellular Carcinoma Invading the Hepatic Vein. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 274-283.	0.2	42
233	The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1363-1370.	1.1	6
234	Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in <sc>K</sc>orea: A nationwide, multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 128-134.	1.4	31

#	ARTICLE	IF	CITATIONS
235	The Effect of Pretransplantation Lamivudine Resistance on the Prognosis of Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2013, 45, 231-235.	0.3	0
236	Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. <i>Nature Methods</i> , 2013, 10, 155-161.	9.0	86
237	Ventriculo-vascular coupling index in asymptomatic mild to moderate aortic stenosis: an important prognostic indicator. <i>European Heart Journal</i> , 2013, 34, P4725-P4725.	1.0	0
238	Small- and Medium-sized Hepatocellular Carcinomas: Monopolar Radiofrequency Ablation with a Multiple-Electrode Switching System—Mid-term Results. <i>Radiology</i> , 2013, 268, 589-600.	3.6	51
239	Hepatocellular Carcinoma: High Hepatitis B Viral Load and Mortality in Patients Treated with Transarterial Chemoembolization. <i>Radiology</i> , 2013, 267, 638-647.	3.6	28
240	A genome-wide association study identified new variants associated with the risk of chronic hepatitis B. <i>Human Molecular Genetics</i> , 2013, 22, 4233-4238.	1.4	105
241	Serum Insulin-like Growth Factor-I Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study. <i>Clinical Cancer Research</i> , 2013, 19, 4218-4227.	3.2	28
242	Efficacy of Adefovir-Based Combination Therapy for Patients with Lamivudine- and Entecavir-Resistant Chronic Hepatitis B Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6325-6332.	1.4	13
243	Guggulsterone attenuates activation and survival of hepatic stellate cell by inhibiting nuclear factor kappa B activation and inducing apoptosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1859-1868.	1.4	15
244	Polymorphisms near Interleukin 28B Gene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence. <i>Intervirology</i> , 2013, 56, 84-90.	1.2	27
245	Association of polymorphism in MicroRNA 219-1 with clearance of hepatitis B virus infection. <i>Journal of Medical Virology</i> , 2013, 85, 808-814.	2.5	22
246	Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation. <i>Liver International</i> , 2013, 33, 884-893.	1.9	19
247	Efficacy of thymosin α -1 plus peginterferon α -2a combination therapy compared with peginterferon α -2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1048-1055.	0.6	19
248	Clinical Prediction of Failure of Lamivudine Prophylaxis for Hepatitis B Virus-Infected Patients Undergoing Cytotoxic Chemotherapy for Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5511-5519.	1.4	15
249	Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 243-250.	1.1	4
250	Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. <i>Journal of Hepatology</i> , 2012, 57, 150-156.	1.8	234
251	Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. <i>Hepatology</i> , 2012, 56, 1792-1803.	3.6	203
252	Association study of genetic variations in microRNAs with the risk of hepatitis B-related liver diseases. <i>Digestive and Liver Disease</i> , 2012, 44, 849-854.	0.4	37

#	ARTICLE	IF	CITATIONS
253	Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 383.	4.5	96
254	Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. <i>Hepatology</i> , 2012, 55, 1443-1452.	3.6	110
255	Nonalcoholic fatty liver disease is associated with coronary artery calcification. <i>Hepatology</i> , 2012, 56, 605-613.	3.6	259
256	Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. <i>Journal of Bioenergetics and Biomembranes</i> , 2012, 44, 101-115.	1.0	39
257	Prognostic implications of tumor vascularity and its relationship to cytokeratin 19 expression in patients with hepatocellular carcinoma. <i>Abdominal Imaging</i> , 2012, 37, 439-446.	2.0	19
258	Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance. <i>Journal of Medical Virology</i> , 2012, 84, 424-430.	2.5	16
259	Risk Factors, Clinical Features, and Prognosis of the Hepatocellular Carcinoma with Peritoneal Metastasis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 813-819.	1.1	31
260	Association of Polymorphism in Pri-microRNAs-371-372-373 with the Occurrence of Hepatocellular Carcinoma in Hepatitis B Virus Infected Patients. <i>PLoS ONE</i> , 2012, 7, e41983.	1.1	23
261	<i>TGFBR3</i> Polymorphisms and Its Haplotypes Associated with Chronic Hepatitis B Virus Infection and Age of Hepatocellular Carcinoma Occurrence. <i>Digestive Diseases</i> , 2011, 29, 278-283.	0.8	11
262	Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1638-1645.	1.4	17
263	Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2130-2136.	1.1	31
264	Genetic Analysis of Complement Component 9 (C9) Polymorphisms with Clearance of Hepatitis B Virus Infection. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2735-2741.	1.1	3
265	No association of TF gene polymorphisms with hepatitis B virus Clearance and hepatocellular carcinoma occurrence in a Korean population. <i>Genes and Genomics</i> , 2011, 33, 209-215.	0.5	0
266	Lack of association between FOS polymorphisms and clearance of HBV infection as well as HCC occurrence. <i>Genes and Genomics</i> , 2011, 33, 327-333.	0.5	0
267	Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. <i>BMC Cancer</i> , 2011, 11, 435.	1.1	22
268	Lack of association of <i>RAD51</i> genetic variations with hepatitis B virus clearance and occurrence of hepatocellular carcinoma in a Korean population. <i>Journal of Medical Virology</i> , 2011, 83, 1892-1899.	2.5	11
269	Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival. <i>Radiology</i> , 2011, 258, 627-634.	3.6	264
270	Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. <i>Acta Pharmacologica Sinica</i> , 2011, 32, 912-920.	2.8	35

#	ARTICLE	IF	CITATIONS
271	Relative Etiological Role of Prior Hepatitis B Virus Infection and Nonalcoholic Fatty Liver Disease in the Development of Non-B Non-C Hepatocellular Carcinoma in a Hepatitis B-Endemic Area. <i>Digestion</i> , 2011, 84, 17-22.	1.2	57
272	Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients. <i>Digestion</i> , 2011, 84, 23-28.	1.2	13
273	High Viremia, Prolonged Lamivudine Therapy and Recurrent Hepatocellular Carcinoma Predict Posttransplant Hepatitis B Recurrence. <i>American Journal of Transplantation</i> , 2010, 10, 1658-1668.	2.6	49
274	Absence of Symptom and Intact Liver Function Are Positive Prognosticators for Patients Undergoing Radiotherapy for Lymph Node Metastasis From Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 729-734.	0.4	18
275	Caudate Lobe Hepatocellular Carcinoma Treated with Selective Chemoembolization. <i>Radiology</i> , 2010, 257, 278-287.	3.6	32
276	CCND2 polymorphisms associated with clearance of HBV Infection. <i>Journal of Human Genetics</i> , 2010, 55, 416-420.	1.1	17
277	Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2010, 298, 9-15.	3.2	49
278	Enterococcus: not an innocent bystander in cirrhotic patients with spontaneous bacterial peritonitis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 21-26.	1.3	18
279	Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 497-507.	1.1	28
280	Complete blood count reflects the degree of oesophageal varices and liver fibrosis in virus-related chronic liver disease patients. <i>Journal of Viral Hepatitis</i> , 2009, 16, 444-452.	1.0	21
281	Putative association of transforming growth factor- β polymorphisms with clearance of hepatitis B virus and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2009, 17, 518-26.	1.0	18
282	Putative association of DNA methyltransferase 1 (DNMT1) polymorphisms with clearance of HBV infection. <i>BMB Reports</i> , 2009, 42, 834-839.	1.1	13
283	Esophageal Varices in Patients with Cirrhosis: Multidetector CT Esophagography Comparison with Endoscopy. <i>Radiology</i> , 2007, 242, 759-768.	3.6	98
284	SPP1 polymorphisms associated with HBV clearance and HCC occurrence. <i>International Journal of Epidemiology</i> , 2007, 36, 1001-1008.	0.9	57
285	Putative Association of Fas and FasL Gene Polymorphisms with Clinical Outcomes of Hepatitis B Virus Infection. <i>Intervirology</i> , 2007, 50, 369-376.	1.2	29
286	HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. <i>Biochemical and Biophysical Research Communications</i> , 2007, 363, 776-781.	1.0	35
287	Evaluation of hernia repair operation in Child-Turcotte-Pugh class C cirrhosis and refractory ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 377-382.	1.4	31
288	IGF2 polymorphisms are associated with hepatitis B virus clearance and hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 38-44.	1.0	26

#	ARTICLE	IF	CITATIONS
289	Association of common promoter polymorphisms of MCP1 with hepatitis B virus clearance. <i>Experimental and Molecular Medicine</i> , 2006, 38, 694-702.	3.2	46
290	Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. <i>Hepato-Gastroenterology</i> , 2006, 53, 266-70.	0.5	16
291	Identification of variants inNFKBIA and association analysis with hepatocellular carcinoma risk among chronic HBV patients. <i>Human Mutation</i> , 2003, 21, 652-653.	1.1	18
292	Association of TNF- α promoter polymorphisms with the clearance of hepatitis B virus infection. <i>Human Molecular Genetics</i> , 2003, 12, 2541-2546.	1.4	132
293	Association of transforming growth factor- β 1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. <i>Experimental and Molecular Medicine</i> , 2003, 35, 196-202.	3.2	74
294	Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. <i>Human Molecular Genetics</i> , 2003, 12, 901-906.	1.4	133
295	Modified Lecompte procedure for the anomalies of ventriculoarterial connection. <i>Annals of Thoracic Surgery</i> , 2001, 72, 176-180.	0.7	15
296	Lecompte procedure for complete transposition of the great arteries with ventricular septal defect and pulmonary stenosis. <i>Annals of Thoracic Surgery</i> , 1994, 57, 876-879.	0.7	12